Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Intrinsic Value
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. [ Read More ]
The intrinsic value of one
ZYDUSLIFE
stock under the Base Case scenario is
557.89
INR.
Compared to the current market price of 983.65 INR,
Zydus Lifesciences Ltd
is
Overvalued by 43%.
Zydus Lifesciences Ltd's market capitalization is 995.5B INR.
ZYDUSLIFE stock price is 983.65 INR.
ZYDUSLIFE stock (557.89 INR) is 43% less than its price (983.65 INR).
ZYDUSLIFE stock (376.34 INR) is 62% less than its price (983.65 INR). Open DCF Valuation
ZYDUSLIFE stock (739.45 INR) is 25% less than its price (983.65 INR). Open Relative Valuation
ZYDUSLIFE has downside potential of 17% compared to the average analyst price target.
Open Wall St Estimates
ZYDUSLIFE's ROE (Return on Equity) has decreased in the last 3 years from 18% to 17%.
ZYDUSLIFE's ROIC (Return on Invested Capital) has increased in the last 3 years from 12% to 14%.
ZYDUSLIFE's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 14%.
ZYDUSLIFE has positive three-year average ROIC (Return on Invested Capital): 12%. The company is efficient at using invested capital to generate operating income.
ZYDUSLIFE's Revenue has grown by 14% over the past 12 months.
ZYDUSLIFE's ROE (Return on Equity) for the past 12 months is positive and is equal to 17%.
ZYDUSLIFE's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
ZYDUSLIFE's Revenue has been growing by 9% per year for the last 3 years.
ZYDUSLIFE has positive Operating Income for the last twelve months.
ZYDUSLIFE has positive Net Income for the last twelve months.
ZYDUSLIFE has positive three-year average ROE (Return on Equity): 20%. The company is efficient at transforming stockholders' equity into net income.
ZYDUSLIFE has positive Free Cash Flow for the last twelve months.
ZYDUSLIFE's short-term assets (99B INR) exceed its short-term liabilties (44B INR).
ZYDUSLIFE has positive Gross Profit for the last twelve months.
ZYDUSLIFE's long-term assets (259B INR) exceed its long-term liabilties (71B INR).
ZYDUSLIFE's D/E (Debt to Equity) is very low and is equal to 0.
ZYDUSLIFE has negative Net Debt. This means that the company has more cash and short-term investments (26B INR) than debt (307m INR).
ZYDUSLIFE's Altman Z-Score is very high and is equal to 8.22.
Valuation Backtest
Zydus Lifesciences Ltd
Run backtest to discover the historical profit from buying and selling
ZYDUSLIFE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Zydus Lifesciences Ltd
Balance Sheet Decomposition
Zydus Lifesciences Ltd
| Current Assets | 99.3B |
| Cash & Short-Term Investments | 25.8B |
| Receivables | 39.2B |
| Other Current Assets | 34.4B |
| Non-Current Assets | 159.4B |
| Long-Term Investments | 11.3B |
| PP&E | 69.4B |
| Intangibles | 58.6B |
| Other Non-Current Assets | 20.2B |
| Current Liabilities | 43.6B |
| Accounts Payable | 16.4B |
| Other Current Liabilities | 27.3B |
| Non-Current Liabilities | 27.8B |
| Long-Term Debt | 307m |
| Other Non-Current Liabilities | 27.5B |
Earnings Waterfall
Zydus Lifesciences Ltd
|
Revenue
|
186.8B
INR
|
|
Cost of Revenue
|
-63.1B
INR
|
|
Gross Profit
|
123.7B
INR
|
|
Operating Expenses
|
-84.6B
INR
|
|
Operating Income
|
39.1B
INR
|
|
Other Expenses
|
-9.4B
INR
|
|
Net Income
|
29.7B
INR
|
Free Cash Flow Analysis
Zydus Lifesciences Ltd
ZYDUSLIFE Profitability Score
Profitability Due Diligence
Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ZYDUSLIFE Solvency Score
Solvency Due Diligence
Zydus Lifesciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Zydus Lifesciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZYDUSLIFE Price Targets Summary
Zydus Lifesciences Ltd
According to Wall Street analysts, the average 1-year price target for
ZYDUSLIFE
is 816.28 INR
with a low forecast of 494.9 INR and a high forecast of 1 162.35 INR.
Shareholder Return
ZYDUSLIFE Price
Zydus Lifesciences Ltd
| Average Annual Return | 19.64% |
| Standard Deviation of Annual Returns | 47.53% |
| Max Drawdown | -18% |
| Market Capitalization | 994.8B INR |
| Shares Outstanding | 1 006 230 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Zydus Lifesciences Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,743 full-time employees. The firm is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The firm has a pipeline for Biologics and Vaccines. The firm offers Lipaglyn to treat diabetic dyslipidemia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The firm in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The firm provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The firm has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.
Contact
IPO
Employees
Officers
The intrinsic value of one
ZYDUSLIFE
stock under the Base Case scenario is
557.89
INR.
Compared to the current market price of 983.65 INR,
Zydus Lifesciences Ltd
is
Overvalued by 43%.
You don't have any saved screeners yet
